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Background: Damage to T cells of the immune system by reactive oxygen species may result in altered cell
function or cell death and thereby potentially impact upon the efficacy of a subsequent immune response. Here,
we assess the impact of the antioxidants Ebselen and N-acetyl cysteine on a range of biological markers in human
T cells derived from a SENIEUR status donor. In addition, the impact of these antioxidants on different MAP kinase
pathways in T cells from donors of different ages was also examined.
Methods: T cell clones were derived from healthy 26, 45 and SENIEUR status 80 year old people and the impact of
titrated concentrations of Ebselen or N-acetyl cysteine on their proliferation and in vitro lifespan, GSH:GSSG ratio as
well as levels of oxidative DNA damage and on MAP kinase signaling pathways was examined.
Results: In this investigation neither Ebselen nor N-acetyl cysteine supplementation had any impact on the
biological endpoints examined in the T cells derived from the SENIEUR status 80 year old donor. This is in contrast
to the anti-immunosenescent effects of these antioxidants on T cells from donors of 26 or 45 years of age. The
analysis of MAP kinases showed that pro-apoptotic pathways become activated in T cells with increasing in vitro
age and that Ebselen or N-acetyl cysteine could decrease activation (phosphorylation) in T cells from 26 or 45 year
old donors, but not from the SENIEUR status 80 year old donor.
Conclusions: The results of this investigation demonstrate that the biological phenotype of SENIEUR status derived
human T cells negates the anti-immunosenescence effects of Ebselen and also N-acetyl cysteine. The results
highlight the importance of pre-antioxidant intervention evaluation to determine risk-benefit.
Keywords: Immunosenescence, Ebselen, NAC, Proliferative capacity, Lifespan, SENIEUR, DNA damage, GSH:GSSG ratio,
MAP kinases, JNK, p38, ERK, Total glutathioneIntroduction
T cells need to undergo rapid clonal expansion upon
antigenic stimulation to produce an immune response.
Any factor that interferes with the ability of T cells to
clonally expand may impact on the effectiveness of an
immune response with the potential to render it sub-
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article, unless otherwise stated.Damage to T cells from reactive oxygen species (ROS),
from both extrinsic and intrinsic (including sites of in-
flammation) sources may result in altered T cell function
or T cell death [1,2]. Mammals have evolved defence sys-
tems, e.g. antioxidants and DNA repair systems, to help
defend against the harmful effects of ROS [3]. Nonethe-
less these defence systems are not perfect, and can be-
come overwhelmed. In addition we have established that
DNA repair capacity declines with age in vivo [4] and in
CD4+ T cell clones (TCCs) cultured in vitro [5,6]. This
lack of optimal performance at all times by the defence
systems may result in an accumulation of DNA damagentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Marthandan et al. Immunity & Ageing 2014, 11:17 Page 2 of 10
http://www.immunityageing.com/content/11/1/17to critical levels within T cells, resulting in cell cycle
arrest or even apoptosis [7], with the potential to impact
adversely on the T cell mediated immune response.
Previous work from our group has provided evidence of
an increase in the level of ROS-induced DNA damage
with age in CD4+ TCCs cultured at 20% O2 [3,8-10] and
an increase in DNA damage and mutation with age in
human lymphocytes [11]. A more recent study demon-
strated anti-immunosenescence effects of two antioxi-
dants, 2-phenyl-1,2-benzisoselenazol-3 (2H)-one (Ebselen;
[12]) or N-acetyl cysteine (NAC; [13]) on CD4+ TCCs
derived from healthy 26 year old and 45 year old donors
[10]. In this paper we now detail the impact of each
of these two antioxidants on CD4+ TCCs derived from a
healthy 80 year old donor (conforming to the SENIEUR
protocol for healthily aged individuals; [14]). The SENIEUR
protocol helps to ensure the rigorous selection of healthily
aged individuals. Evidence from the literature suggests an
age-associated compromise of T cell function [15]. An in-
verse relationship between replicative capacity and donor
age of TCCs has previously been reported [16]. However,
there are exceptions where a straightforward relationship
between age and T cell function breaks down. T cells from
very healthy elderly donors, including those selected using
the SENIEUR protocol [14] is one exception. In these cases
individuals have been shown to be able to raise an effective
immune response, contributed to by adequate T cell func-
tion [17-19]. We were interested to examine whether the
anti-immunosenescent effects of Ebselen or NAC, which
we have previously reported, in TCCs from donors of 26
or 45 years of age [10] were also present when TCCs from
a SENIEUR selected healthy aged donor were tested.
Ebselen is a lipid soluble seleno-organic compound
having glutathione peroxidase like activity which enables
them to scavenge hydroxyl radicals and peroxides using
glutathione (GSH) as a substrate [20]. Furthermore,
Ebselen has the capability to inhibit the release of apop-
totic factor cytochrome c [21]. The antioxidant potential
of Ebselen has been previously demonstrated in a num-
ber of other cell lines; HepG2 cells [20], human HL-60
[22] and PC-12 cells [23]. Their ability to scavenge intra-
cellular ROS resulting in reduction of hydroxyl radical
formation may have contributed to the antioxidant po-
tential in TCCs derived from healthy 26 and 45 year old
donors displayed by their impact on certain markers of
T cell integrity and function [10].
In terms of NAC, the presence of acetylated form of the
amino acid L-cysteine and sulfhydryl groups enables them
to act as a precursor of GSH synthesis and neutralise free
radicals respectively [24]. Glutamate and cysteine share
the same transporter in the body and elevation in levels
of extracellular glutamate competitively inhibit cysteine
transport resulting in depletion of intracellular GSH syn-
thesis. The ability of NAC to raise GSH levels due to itscapacity to donate cysteine amino acid may also supple-
ment its antioxidant potential [25]. Previous studies have
revealed the ROS scavenging potential of NAC in HeLa
cells [26] and HepG2 cells [20].
Although they can cause damage within living systems,
ROS act as signals/mediators in a variety of cellular pro-
cesses including; cell function, proliferation, differenti-
ation, cell damage and death. ROS act as intracellular
signalling molecules within T cells [27], and they can
mediate their effects via several signalling molecules
such as calcium, protein tyrosine kinases (PTKs), protein
tyrosine phosphatases (PTPs), serine/threonine kinases
and phospholipases. ROS have been revealed to control
cell proliferation induced by lectin and have an estab-
lished role in protein tyrosine phosphorylation and acti-
vation of JNK1 [28]. Mitogen activated protein (MAP)
kinases, a prominent family of protein kinases, operate
through several pathways including, extracellular signal
regulated kinases (ERK), c-Jun N-terminal kinase (JNK)
and p38 kinase. These pathways are involved in proli-
feration, differentiation and apoptosis [23,29,30]. In the
novel study described in this paper, the impact of Ebselen
or NAC on different MAP kinase pathways in human
CD4+ TCCs derived from healthy 26, 45 and 80 year old
donors has also been investigated in an attempt to un-
derstand the contributory factors to any alterations in
the biological endpoints measured in the supplemented
TCCs.Methods
Culture of TCCs and determination of their proliferative
capacity and lifespan
Clone 399-37 was derived from a healthy 80 year old
donor (conforming to the SENIEUR protocol for health-
ily aged individuals; [14]), Clones 400-23 and 385-7 were
derived from a healthy 26 and 45 year donor respec-
tively. Three independently derived ([31] – general refe-
rence for deriving the TCCs) human CD4+ TCCs of
each of the three donors were separately maintained in
culture in 24 well plates (5 wells, 2 ml medium per well)
containing serum-free medium, X-Vivo 10 (Bio Whittaker)
at concentrations of 2-4 × 105 cells per well, along with
2 × 105 gamma-irradiated (80 Gy) RJK853 cells per well
(EBV-transformed B-lymphoblastoid cell line with com-
plete hprt deletion), as feeder cells. The clones were main-
tained at 37°C under conditions of 5% CO2 and 95% air
atmosphere and supplemented with 400 U/ml recombin-
ant IL-2 (Chiron, UK) on days 1 and 4 of the 7 days cycle.
A viable cell count was performed on harvested cells using
a Neubauer Counting Chamber, and a new culture cycle
was set up with fresh medium and RJK853 feeder cells on
day 7 [3,8]. The proliferative capacity and lifespan were de-
termined similar to the protocol described previously
Marthandan et al. Immunity & Ageing 2014, 11:17 Page 3 of 10
http://www.immunityageing.com/content/11/1/17[3,8,10]. The TCCs used in this study were kindly provided
by the group of Professor Graham Pawelec.Ebselen or NAC supplementation of TCCs
Further to our previous study [10] we examined the im-
pact of titrated concentrations of Ebselen (0, 10, 30, 60,
100 μM) or NAC (0, 1.25, 5, 7.5, 10 mM) in three pooled
399-37 (80 year old) TCCs, 385-7 (45 year old) TCCs
and 400-23 (26 year old) TCCs respectively. n = 3 in
each case.Determination of levels of oxidative damage to DNA in
TCCs derived from a healthy 80 year old donor
The levels and types of DNA damage in TCCs, sup-
plemented with or without antioxidants, at various time
points throughout their lifespan were assessed using a
modified alkaline comet assay [3,8,10].Quantitative determination of GSH:GSSG ratio and total
glutathione level in TCCs derived from a healthy 80 year
old donor
A GSH:GSSG ratio assay kit was used to determine the ra-
tio of reduced glutathione (GSH) to oxidized glutathione
(GSSG), and total glutathione levels [10].Assessing the impact of antioxidant supplementation on
MAP kinase signalling pathways in TCCs derived from
donors of all three ages using SDS-polyacrylamide gel
electrophoresis (PAGE) and Western Blotting
Ebselen or NAC supplemented and non-supplemented
clones were harvested at different stages of their lifespan
(at different PDs). Cells were washed in 1×PBS (pH 7.4).
To prepare samples for western blot, cells were counted
in a Neubauer Counting Chamber and an appropriate
amount of cells were re-suspended in loading buffer and
incubated at 90°C for 10 minutes. The samples were
stored at -20°C and later used for SDS-PAGE. Loading
buffer consists of 4% SDS, 40% Glycerin, 50 mM Tris/
HCL (pH 6.8), 50 mM Dithiothreitol (DTT) and bromo-
phenol blue. Whole cell extracts were electrophoresed
on SDS-PAGE and transferred to nitrocellulose mem-
branes (Protran; Schleicher and Schuell). The membrane
was blocked in 5% skimmed milk/TBS-T (0.5 M Tris
Base, 9% NaCl, 0.5% Tween 20, pH 8.4; Tween 20 [Carl
Roth]) and incubated with protein-specific primary anti-
bodies followed by horseradish peroxidase–conjugated
species-specific secondary antibodies (Jackson Immuno-
Research Laboratories, Inc.). Signals were detected using
the ECL reagent (GE Healthcare) on imaging film (BioMax;
Kodak). Western Blot for Anti-β- Actin was performed as
the loading control.Quantification of phosphorylated and total MAP kinase
protein expression levels in TCC samples derived from
donors for all the three ages
For immunodetection, primary antibodies were used at
the following dilutions: Phospho JNK (1:50; 9251), Phos-
pho p38 (1:100; 9211), Phospho p44/p42 [ERK1/2] (1:500;
9101), Phospho c-Jun (1:50; 2361), SAPK / JNK (1:50;
9252), p38 (1:100; 9212), p44/p42 [ERK1/2] (1:600;
4695) and Anti-β- Actin (1:10,000; A5316). All anti-
bodies except Anti-β-Actin were purchased from Cell
Signaling Technology, Boston, USA. Anti-β-Actin was
purchased from Sigma-Aldrich. Secondary antibodies,
conjugated to horseradish peroxidase (Dako) were used at
1:10,000 dilution and blots developed using ECL detection
system and radiographic film (GE Healthcare, Germany).
After the film development, quantification of the signal in-
tensities of the bands in the Western blots was carried out
using the Metamorph software [32]. The signal intensities
of the bands representing the levels of phosphorylated or
total proteins were normalized to the reference band of
Anti-β- Actin.
Statistical analysis of the samples
The results were tested for significance using paired
two-sample type 2 Student’s t-tests assuming equal va-
riances; p values are presented as appropriate.
Results
Effects of Ebselen and NAC on intracellular redox status
(GSH:GSSG ratio) and total glutathione levels in human
TCCs in vitro derived from a healthy 80 year old donor
TCC samples were taken from the cultures at various
time points during their lifespan and the effect of 30 μM
Ebselen or 7.5 mM NAC on intracellular redox status
(GSH:GSSG ratio) and total glutathione levels within the
T cells were determined. Figure 1A and B show the re-
sults of the effect of 30 μM Ebselen or 7.5 mM NAC on
the GSH:GSSG ratio.
Supplementation of TCCs from a young “in vitro age”
with 30 μM Ebselen (Figure 1A) or 7.5 mM NAC
(Figure 1B) had no impact on the GSH:GSSG ratio at
any of the time points examined when compared to
non-supplemented clones.
In both cases (antioxidant supplemented and non-
supplemented), the GSH:GSSG ratio significantly de-
creased with increased time in culture (Additional file 1:
Table S1A and B). A similar scenario was observed in
TCCs derived from a healthy 26 and 45 year old donor in
our previous study [10]. Furthermore, the GSH:GSSG ra-
tio was significantly lower in TCCs derived from a healthy
80 year old donor (supplemented and non-supplemented)
compared to the GSH:GSSG ratio in TCCs derived from
either of the healthy young aged donors (26 and 45 year
old; Tables 1 and 2; [10]).
Figure 1 Impact of 30μM Ebselen or 7.5mM NAC supplementation on GSH:GSSG ratio in TCCs derived from a healthy 80 year old
donor. (A & B) The impact of 30 μM Ebselen (A) or 7.5mM NAC (B) on GSH:GSSG ratio in three pooled TCCs derived from a healthy 80 year old
donor. The bars indicate the mean ± S.D.
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mM) investigated in this study had any impact on total
glutathione levels, at any of the three time points in
TCCs derived from a healthy 80 year old donor com-
pared to non-supplemented clones, as was the case for
GSH:GSSG ratio. However, the levels of total glutathione
were significantly lower in the 399-37 TCCs compared
to levels in TCCs from both younger aged donors (Data
not shown).
The impact of Ebselen and NAC on in vitro proliferative
capacity and lifespan of human TCCs derived from a
healthy 80 year old donor
The TCCs used in this study underwent apoptosis at the
end of their lifespan after completing a finite number of
PDs. This is in line with previous reports [3,33].
The effect of different concentrations of Ebselen (0, 10,
30 μM) or NAC (0, 1.25, 5, 7.5 mM) on the proliferative
capacity and in vitro lifespan of TCCs was investigated by
supplementing them with one of the either antioxidants
until the end of their lifespan. The results presented inTable 1 GSH:GSSG ratio of TCCs + / - Ebselen
Times in culture (Weeks) 30μM ebselen 400-23
2 - 42.3 ± 1.7
2 + 44.0 ± 1.7
5 - 44.2 ± 2.8
5 + 47.3 ± 2.4
9/10 - 36.1 ± 1.6
9/10 + 37.2 ± 1.4
GSH:GSSG ratios in three pooled CD4+ TCCs (+ / - 30 μM Ebselen) derived from a h
pooled TCCs, each derived from a healthy 26 or a 45 year old donor (published dat
*Significantly lower GSH:GSSG ratio in 399-37 clones (80 year old) compared to eithTable 3 indicate that Ebselen (30 μM) and NAC (7.5 mM)
supplementation of TCCs derived from a healthy 80 year
old donor resulted in a slight decrease in the average
number of PD accomplished per week, though not sta-
tistically significant. Neither of the antioxidants had any
significant impact on the cumulative level of PDs achieved
before the end of their lifespan in the TCCs derived from
a healthy 80 year old donor, in contrast to the significantly
enhanced PDs in antioxidant supplemented TCCs derived
from the healthy younger donors ([10]; Table 3). However,
30 μM Ebselen or 7.5 mM NAC supplemented TCCs were
able to survive in culture for an additional week and three
weeks respectively compared to non-supplemented TCCs.
Other concentrations investigated in the study, 10 μM
Ebselen and 1.25 or 5 mM NAC did not reveal an impact
on either proliferative capacity or lifespan in TCCs derived
from a healthy 80 year old donor. Higher concentrations
of Ebselen (60-100 μM) or NAC (10 mM) used in this
investigation completely inhibited the growth of TCCs de-
rived from a healthy 80 year old donor within a week of
culture (Data not shown). A similar scenario was observed(26 yr ol) 385-7 (45 yr old) 399-37 (80 yr old)
44.3 ± 2.4 37.7 ± 0.4*
41.9 ± 1.2 36.7 ± 0.9*
42.0 ± 1.8 30.8 ± 2.0*
46.8 ± 5.1 31.3 ± 1.5*
33.4 ± 4.1 25.5 ± 0.7*
36.3 ± 2.9 26.6 ± 0.8*
ealthy 80 year old donor are significantly lower than in either of the three
a from [10]).
er 400-23 (26 year old) or 385-7 (45 year old) clones.
Table 2 GSH:GSSG ratio of TCCs + / - NAC
Time in culture (Weeks) 7.5 mM NAC 400-23 (26 yr old) 385-7 (45 yr old) 399-37 (80 yr old)
2 - 46.3 ± 2.5 44.2 ± 0.8 36.7 ± 1.0*
2 + 51.2 ± 4.5 46.7 ± 3.3 35.7 ± 0.9*
5 - 37.9 ± 0.8 41.0 ± 0.5 29.4 ± 1.2*
5 + 42.5 ± 2.5 46.1 ± 0.3 30.7 ± 1.8*
9/10 - 35.5 ± 4.0 33.2 ± 3.1 24.2 ± 0.2*
9/10 + 35.8 ± 2.3 36.6 ± 2.6 24.1 ± 0.2*
GSH:GSSG ratios in three pooled CD4+ TCCs (+ / - 7.5 mM NAC) derived from a healthy 80 year old donor are significantly lower than the levels in either of the
three pooled TCCs, each derived from a healthy 26 or a 45 year old donor (published data from [10]).
*Significantly lower GSH:GSSG ratio in 399-37 clones (80 year old) compared to either 400-23 (26 year old) or 385-7 (45 year old) clones.
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26 and 45 year old donor was supplemented with high
concentrations of either Ebselen (60-100 μM) or NAC
(10 mM), [10]. Furthermore, as explained in our previous
study [10], mechanisms behind the pro-apoptotic effect
of high concentrations of antioxidants have also been
demonstrated in other model systems [34-36].The impact of ebselen or NAC on levels of oxidative DNA
damage in human TCCs as a function of in vitro age
Aliquots of TCC samples were taken from culture at va-
rious time points and the effect of 30 μM of Ebselen or
7.5 mM of NAC on the levels of oxidative DNA damage
within the T cells were determined. In control (non-sup-
plemented) samples, levels of oxidative damage to DNA
increased as a function of age, as measured by the modi-
fied endonuclease III (Endo III) and formamidopyrimidineTables 3 Proliferative capacity and lifespan of TCCs on antiox
Clone (Age of the donor) Initial PD Concentration Average PD p
400-23 (26 year old donor) 34.5
Control 0.7 ± 0.1
30 μM Ebselen 1.2 ± 0.2
385-7 (45 year old donor) 31.0
Control 1.0 ± 0.1
30 μM Ebselen 1.4 ± 0.4
399-37 (80 year old donor) 31.1 Control 1.2 ± 0.2
30 μM Ebselen 1.2 ± 0.1
Clone (Age of the donor) Initial PD Concentration Average PD p
400-23 (26 year old donor) 34.5
Control 0.7 ± 0.1
7.5 mMNAC 1.2 ± 0.2
385-7 (45 year old donor) 31.0
Control 1.0 ± 0.1
7.5 mMNAC 1.4 ± 0.4
399-37 (80 year old donor) 31.1
Control 1.1 ± 0.2
7.5 mMNAC 0.9 ± 0.2
Effect of Ebselen or NAC supplementation on the proliferative capacity and lifespan
Data of 26 and 45 year old donors are published data from [10]. *Significantly high
n = 3 pooled TCCs for each age group.DNA glycosylase (FPG) comet assays, in line with previ-
ously published findings [3,9].
The results presented in Figure 2A and B reveal that oxi-
dative DNA damage levels increased as a function of time
in culture, in both supplemented and non-supplemented
clones. Neither dose of antioxidants including 30 μM for
Ebselen and 7.5 mM for NAC had any impact on the levels
of oxidative DNA damage in TCCs during their span in
culture. Figure 2 summarises the data obtained following
30 μM Ebselen (A) or 7.5 mM NAC (B) supplementation.
The levels of oxidative DNA damage significantly in-
creased with time in culture in both supplemented and
non-supplemented TCCs derived from a healthy 80 year
old donor (Table 4). This was also the case in TCCs
derived from a healthy 26 or 45 year old donor [10]. A
comparison of the levels of oxidative DNA damage in
the 399-37 clone samples with those from the younger
donors revealed that basal levels of oxidative DNA damageidant supplementation
er week Cumulative PD achieved at the end of lifespan in culture
44.7 ± 0.3*
56.2 ± 0.4*
44.4 ± 0.3*
50.8 ± 0.4*
45.0 ± 0.4
44.6 ± 0.3
er week Cumulative Pd achieved at the end of lifespan in culture
44.7 ± 0.3*
56.1 ± 0.3*
44.4 ± 0.3*
55.8 ± 0.4*
44.2 ± 0.5
42.3 ± 0.4
of CD4+ TCCs derived from healthy 26, 45 or 80 year old donors.
er cumulative PDs in supplemented (+) clones compared to controls (-).
Figure 2 Effect of 30μM Ebselen or 7.5mM NAC supplementation on the levels of oxidative DNA damage in TCCs derived from a
healthy 80 year old donor. (A & B) The impact of 30 μM Ebselen (A) or 7.5mM NAC (B) on the levels of oxidative DNA damage in three
pooled TCCs derived from a healthy 80 year old donor. The bars indicate the mean ± S.D.
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sampled time points (Additional file 1: Table S2A and B).
The impact of ebselen or NAC on different MAP kinase
pathways in human TCCs derived from donors of
different ages
The impact of Ebselen or NAC supplementation on
MAP kinase phosphorylation status and total protein
levels was determined in TCC samples from healthy young
(26 year old), middle aged (45 year old) and elderly (80 year
old) donors.Tables 4 Levels of oxidative DNA damage in TCCs on antioxid
Time in culture (Weeks)
30 μM Ebselen (% of DNA in comet t
-
Alk End
2 19.7 ± 0.6 21.6 ± 0.6
5 25.6 ± 0.6 27.6 ± 0.4
10 46.9 ± 0.6 48.8 ± 0.7
* *
Time in culture (Weeks)
7.5 mM NAC (% of DNA in comet tail
-
Alk End
2 21.8 ± 0.8 22.6 ± 0.6
5 28.2 ± 1.6 30.8 ± 0.8
10
48.7 ± 0.4 49.9 ± 0.7
* *
The increase in levels of oxidative DNA damage in CD4+ TCC derived from a health
*Significantly higher levels of oxidative DNA damage in week 10 on comparison wiFigure 3A reveals that ERK was similarly phosphorylated
in Ebselen supplemented or control TCCs, irrespective of
TCC in vitro age (PD). In contrast, JNK, p38 and c-Jun
phosphorylation levels were absent (or low) in young cells
(Y) but greatly enhanced in late PD cells (O) from all do-
nors. 30 μM Ebselen did not significantly alter the increase
of p38 phosphorylation in late PD TCCs. There was a sig-
nificant reduction in JNK and c-Jun phosphorylation in
young and middle-aged donor TCCs on Ebselen supple-
mentation. However, Ebselen did not result in a reduction
in JNK or c-Jun phosphorylation in TCCs derived from aant supplementation
ail)
+
Fpg Alk End Fpg
22.5 ± 0.6 20.6 ± 0.8 22.5 ± 0.8 23.5 ± 0.8
31.7 ± 0.8 26.3 ± 1.2 30.1 ± 1.0 32.0 ± 1.1
51.2 ± 1.2 48.8 ± 0.7 49.8 ± 0.6 51.8 ± 2.1
* * * *
)
+
Fpg Alk End Fpg
23.7 ± 0.3 22.2 ± 0.3 23.9 ± 0.1 24.2 ± 0.2
33.0 ± 1.2 27.7 ± 1.2 32.9 ± 0.8 34.1 ± 0.3
52.6 ± 1.0 50.2 ± 0.3 52.2 ± 1.2 53.6 ± 0.9
* * * *
y 80 year old donor supplemented + / - 30 μM Ebselen or 7.5 mM NAC.
th the earlier weeks (2 and 5). n = 3 pooled TCCs for each age group.
Figure 3 Impact of 30 μM Ebselen (A) or 7.5 mM NAC (B) on the phosphorylation levels of JNK, c-Jun, p38 and ERK. The blots reveal the
effect of antioxidant supplementation between the young (early PD) and aged (late PD) TCCs isolated from healthy 26, 45 or 80 year old donors
compared to non-supplemented controls.
Marthandan et al. Immunity & Ageing 2014, 11:17 Page 7 of 10
http://www.immunityageing.com/content/11/1/17healthy 80 year old donor (80, O, +). Quantification of the
signal intensities of the bands in the Western blots were
performed for both supplemented and non-supplemented
clones (Additional file 1: Figure S1A-L).
A similar pattern of phosphorylation is seen in the
young (early PD) TCCs with and without 7.5 mM NAC
supplementation, with only ERK phosphorylated to any
significant extent (Figure 3B). Phosphorylation of JNK,
p38 and c-Jun was absent (or low) in young cells (Y) but
greatly enhanced in aged cells (O) from all donors.
7.5 mM NAC supplementation inhibited this phospho-
rylation by at least 80% (Figure 3B) in young (26 year
old) and middle aged (45 year old) donor TCCs with the
exception of p-JNK in the middle aged donor TCC
where a lower reduction was seen (~25%). However, no
significant reduction in phosphorylation of JNK, p38,
and c-Jun was found in TCCs derived from a healthy 80
year old donor treated with 7.5 mM NAC (80, O, +).
Quantification of the signal intensities of the bands inthe Western blots were performed for both supple-
mented and non-supplemented clones (Additional file 1:
Figure S2A-L).
The total levels of JNK, p38 and ERK (Additional file 1:
Figure S3C and D) were not significantly different follo-
wing 30 μM Ebselen or 7.5 mM NAC, compared to non-
supplemented controls.
Discussion
Previous work from our group demonstrated the anti-
immunosenescence potential of certain concentrations
of Ebselen (30 μM) or NAC (7.5 mM) in CD4+ T cells
ex vivo and in CD4+ TCCs when supplemented from a
young in vitro age [10]. The ROS scavenging potential of
these antioxidants resulted in enhancement of the GSH:
GSSG ratio, a significant decrease in levels of oxidative
DNA damage and a significant increase in lifespan, and/
or proliferative capacity of TCCs derived from a healthy
26 year old or 45 year old donor.
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TCC derived from a healthy 80 year old donor (conform-
ing to the SENIEUR protocol; [14]) with 30 μM Ebselen
or 7.5 mM NAC, from a young in vitro age (31.1 Initial
PD) did not significantly alter the lifespan, the prolifera-
tive capacity (Table 3), levels of oxidative DNA damage
(Figure 2A and B), intracellular redox status (GSH:GSSG
ratio; Figure 1A and B) or the total glutathione levels.
Barnett and colleagues have previously published that
20 mM Carnosine (an antioxidant) supplementation
from the midpoint of their in vitro lifespan did not alter
the longevity of TCCs derived from an 80 year old donor
[3]. In that case, it was suggested that Carnosine may
not have been able to reveal its antioxidant potential due
to the high background of biomolecule damage that
already existed in these T cells, accumulated during ear-
lier stages of their in vitro lifespan under conditions of
20% O2 that may have compromised a range of intracel-
lular systems. One piece of evidence in this regard is the
measured increase in basal levels of oxidative DNA in
TCCs from a healthy 80 year old donor, compared with
basal levels in TCCs from healthy 26 or 45 year old
donors (Additional file 1: Table S2A, B). The results ob-
tained in this current investigation suggest that a range
of antioxidant supplementations do not have an impact
on the biological endpoints measured in the TCCs from
healthy 80 year old donors.
A similar scenario is applicable in terms of the GSH:
GSSG ratio. Intracellular redox status (as reflected in the
GSH:GSSG ratio) is an important mechanism having an
invaluable role as a mediator in apoptosis in many cell
systems [37]. Previous findings reveal that intracellular
reduced glutathione (GSH), a main determinant of in-
tracellular redox status, is depleted before the onset of
apoptosis [38]. The GSH:GSSG redox couplet maintains
the redox environment of the cell and GSH is abundant
in the cell [39]. The oxidation of even a small amount of
GSH results in the formation of GSSG thereby lowering
the GSH:GSSG ratio suggested to be responsible for
several human diseases [40]. However, in this study, the
GSH:GSSG ratio did not significantly change on antioxi-
dant supplementation compared to the non-treated con-
trols, and the ratio decreased as cells approached the
latter stage of their in vitro lifespan.
Although ROS are generally thought of as harmful
molecules, they do play an important role in T cell sig-
nalling events [41] including the MAP kinase pathways.
MAP kinases have several pathways identified including
ERK, JNK and the p38 kinase pathways. ERK phospho-
rylation has been shown to act as a cell survival factor
against oxidative stress, whereas phosphorylation of JNK
and p38 contributes to cell death machinery [23]. T cell
signalling events such as protein tyrosine phosphorylation
and activation of JNK as well as cellular proliferationinduced by lectin are some of the few instances that re-
quire the presence of ROS [28]. Reduced ROS levels might
interfere with the signalling pathways involved in T cell ac-
tivation and proliferation, for example, the redox-sensitive
activation of transcription factors such as nuclear factor
kappa light chain enhancer of activated B cells (NF-kB) or
activator protein-1 (AP-1) [42].
This paper describes the investigation of the effect of
the antioxidants, Ebselen or NAC, on the phosphoryl-
ation of p38 and JNK (SAPK) in TCCs from donors of
different ages. JNK activation primarily results in apop-
tosis by the phosphorylation of c-Jun (serine 63), which
is a component of the transcription factor complex AP-1
that binds to a specific DNA sequence in the AP-1 site [43]
resulting in increase of DNA binding and ultimately apop-
tosis. Previous findings have indicated inhibition of H2O2-
induced p38 MAP kinase activation, c-Jun phosphorylation
and JNK activation by Ebselen in a concentration-
dependent manner [23]. Furthermore, earlier studies
have revealed that NAC decreased both JNK and p38
phosphorylation induced by 2,3,5-tris-(glutathion-S-yl)
hydroquinone (TGHQ) in human epithelial cells [44], sel-
enite in hepatocytes [29] and taxol (chemotherapeutic
agent) in leukaemic cells [30]. The results of the present
study suggest that pro-apoptotic pathways become acti-
vated in all TCCs as the cells reach an ‘old’ in vitro age
with activation of JNK, p38 and c-Jun across all old TCCs
irrespective of donor age (Figure 3A and B). The results of
our study also reinforce the radical scavenging potential of
Ebselen and NAC with a significant decrease in phospho-
rylation of JNK and c-Jun in late PD TCCs in vitro derived
from a healthy 26 or 45 year old donor on supplemen-
tation with 30 μM Ebselen (Figure 3A) or 7.5 mM NAC
(Figure 3B) compared to non-supplemented TCCs, al-
though only NAC supplementation was able to decrease
p38 phosphorylation in these late PD TCCs. However, nei-
ther antioxidant could significantly alter phosphorylation
of p38, JNK or c-Jun in late PD TCCs in vitro derived
from a healthy 80 year old donor (Figure 3A and B). Our
results suggest that neither Ebselen nor NAC could alter
the activation of p38, JNK and c-Jun in TCCs from very
healthy elderly donors and thus fail to impact upon the
time to onset of apoptosis. This is another piece of
evidence which suggests that there are alterations to intra-
cellular processes, which have accumulated during the
prolonged existence of T cells from elderly donors.
In contrast to the results obtained from our study,
others have published that NAC supplementation in-
creased ERK activation in human kidney proximal tu-
bule epithelial cells (HK-2) [44]. However, results from
this present study revealed consistent activation of ERK
in all TCCs irrespective of donor or in vitro age with no
significant change in the levels of ERK phosphorylation
in any of the age groups upon supplementation with
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non-supplemented TCCs (Figure 3A and B).
The results of this study highlight a heterogeneous
potential of Ebselen or NAC as anti-immunosenescent
interventive strategies in human T cells. If in vivo anti-
oxidant supplementation is to be attempted then careful
pre-intervention evaluation should be undertaken to de-
termine risk-benefit.
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